Tempus Immune Profile Score (IPS)
Use
The Tempus Immune Profile Score (IPS) is used as a prognostic indicator for adult patients with metastatic and/or stage IV pan-solid tumor disease who are candidates for immune checkpoint inhibitor (ICI) therapy. It classifies patients into IPS-High or IPS-Low groups, with IPS-High patients showing a higher overall survival when treated with ICI-based regimens.
Special Instructions
IPS may be ordered as an add-on with xT CDx & xR combination or xT & xR combination. Both DNA and xR RNA seq are required for processing.
Limitations
IPS is relevant for prostate, lung, colorectal, renal, and other major cancer types associated with ICI treatments. It's validated for PD-L1, TMB, and MSI statuses but doesn't replace existing diagnostic methodologies entirely.
Methodology
NGS
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Not provided.